OncologyConcentrated betData as of 2026-11-15
Urothelial Cancer is a concentrated bet: only 4 US-listed developers are in the clinic, and the median one is worth $1.2B against a $1.03B universe median.
Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.
EXEL alone accounts for 87% of the $19.4B of market capitalisation competing here, so this is a leader plus a tail rather than a level race.
$2.7B of allocated capital sits in Urothelial Cancer, ranking it 71st of 299 indications by the money committed to it.
| Ticker | Company | Lead asset | Phase | Trials | Market cap | Pure play | Indications | Next catalyst |
|---|---|---|---|---|---|---|---|---|
| EXEL | Exelixis | Cabozantinib | Phase 1 | 1 | $16.8B | No | 10 | 3 Mar 2027 |
| GENB | Generate Biomedicines | GB-4362 | Phase 1 | 1 | $1.5B | No | 3 | No dated event |
| AKTS | Aktis Oncology | Ac-AKY-1189 | Phase 1 | 2 | $924M | No | 2 | No dated event |
| MGNX | MacroGenics | MGC030 | Phase 1 | 1 | $140M | No | 2 | 30 Jun 2027 |
Sorted by phase, then by market capitalisation. Ticker links open the company profile. EXEL holds 87% of the $19.4B competing in this indication.
Few competitors, each one large. The market pays a scarcity premium to compete here.
Oncology holds $154B of the map's capital, 26.9% of the total, spread across 93 indications and 93 companies. 38 of those indications have more than one company competing.
See every Oncology indication on the mapExelixis (EXEL, Cabozantinib, Phase 1); Generate Biomedicines (GENB, GB-4362, Phase 1); Aktis Oncology (AKTS, Ac-AKY-1189, Phase 1); MacroGenics (MGNX, MGC030, Phase 1). Those are the 4 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Urothelial Cancer.
Of the 4 clinical-stage programmes in Urothelial Cancer, 0 are in Phase 3 or filed, 0 are in mid-stage development and 4 are in early-stage development.
EXEL is the largest developer in Urothelial Cancer, holding 87% of the $19.4B of market capitalisation competing in the indication. The median competitor is worth $1.2B.
The next dated catalyst in Urothelial Cancer is EXEL on 3 Mar 2027. 2 dated events across the field fall in the next 12 months.
Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.
Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.
Back to the disease map